We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
-2.82%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.01B
AUM Growth
-$1.27B
(-30%)
Cap. Flow
-$929M
Cap. Flow
% of AUM
-30.83%
Top 10 Holdings %
Top 10 Hldgs %
32.92%
Holding
106
New
21
Increased
16
Reduced
41
Closed
22
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$89.8M |
| 2 |
Becton Dickinson
BDX
|
+$70.5M |
| 3 |
Zoetis
ZTS
|
+$66.8M |
| 4 |
Merck
MRK
|
+$64.8M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$60.5M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
+$218M |
| 2 |
argenx
ARGX
|
+$127M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
+$125M |
| 4 |
Boston Scientific
BSX
|
+$113M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$100M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arvinas
ARVN
$534M
| $117M | 3.88% |
4,273,900
-676,100
| -14% | -$21.4M |
|
2
Surgery Partners
SGRY
$2.08B
| $116M | 3.84% |
3,355,900
+243,900
| +8% | +$7.92M |
|
|
3
Bio-Rad Laboratories Class A
BIO
$7.91B
| $106M | 3.52% |
221,500
+129,300
| +140% | +$60.5M |
|
|
4
argenx
ARGX
$54B
| $105M | 3.47% |
280,700
-344,300
| -55% | -$127M |
|
5
Jazz Pharmaceuticals
JAZZ
$15B
| $99.2M | 3.29% |
677,900
-49,641
| -7% | -$7.34M |
|
|
6
Regeneron Pharmaceuticals
REGN
$69.7B
| $97.9M | 3.25% |
+119,100
| New | +$89.8M |
|
|
AKRO
7
DELISTED
Akero Therapeutics
AKRO
| $93.6M | 3.11% |
2,447,000
-1,378,000
| -36% | -$61.4M |
|
8
Tenet Healthcare
THC
$16.6B
| $87.5M | 2.9% |
1,472,000
+754,700
| +105% | +$41.9M |
|
9
Ultragenyx Pharmaceutical
RARE
$3.12B
| $85.3M | 2.83% |
2,126,900
-863,100
| -29% | -$37M |
|
10
Universal Health Services
UHS
$8.96B
| $85.2M | 2.83% |
670,000
-155,600
| -19% | -$21.5M |
|
11
Acadia Healthcare
ACHC
$2.97B
| $84.2M | 2.79% |
1,165,300
+300
| +0% | +$23.4K |
|
|
12
Neurocrine Biosciences
NBIX
$17.3B
| $82.6M | 2.74% |
815,700
-964,300
| -54% | -$100M |
|
13
Syndax Pharmaceuticals
SNDX
$2.08B
| $81.6M | 2.71% |
3,865,300
-1,995,700
| -34% | -$49.6M |
|
|
KRTX
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $73.3M | 2.43% |
403,800
+104,800
| +35% | +$20M |
|
|
15
Becton Dickinson
BDX
$42.7B
| $71.3M | 2.37% |
+288,000
| New | +$70.5M |
|
16
Pliant Therapeutics
PLRX
$69.4M
| $70.9M | 2.35% |
2,665,000
+424,600
| +19% | +$12.1M |
|
|
17
Zoetis
ZTS
$31.2B
| $67.8M | 2.25% |
+407,500
| New | +$66.8M |
|
|
VTYX
18
DELISTED
Ventyx Biosciences
VTYX
| $64.2M | 2.13% |
1,917,800
+632,800
| +49% | +$24.6M |
|
|
19
Merck
MRK
$305B
| $63.8M | 2.12% |
+600,000
| New | +$64.8M |
|
20
Sarepta Therapeutics
SRPT
$1.86B
| $57.3M | 1.9% |
416,000
-639,000
| -61% | -$82.9M |
|
21
Legend Biotech
LEGN
$4.46B
| $54M | 1.79% |
1,120,500
+150,500
| +16% | +$7.36M |
|
22
Prothena Corp
PRTA
$441M
| $51.8M | 1.72% |
1,068,200
-1,884,800
| -64% | -$99.6M |
|
23
IDEAYA Biosciences
IDYA
$3.54B
| $50.4M | 1.67% |
3,673,400
-151,400
| -4% | -$2.52M |
|
24
Zentalis Pharmaceuticals
ZNTL
$340M
| $50.4M | 1.67% |
2,929,300
-2,220,700
| -43% | -$45M |
|
|
ISEE
25
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $45.5M | 1.51% |
1,869,200
+1,030,793
| +123% | +$22.6M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH